Swetter SM, Johnson D, Albertini MR, et al. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2024. Accessed April 10, 2024. Available at: https://www.nccn.org

• PubMed
Swetter SM, Johnson D, Albertini MR, NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2024. Accessed April 10, 2024. Available at: https://www.nccn.org)| false
• Search Google Scholar
• Export Citation

Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019;20:948–960.

• PubMed
Rozeman EA, Menzies AM, van Akkooi ACJ, Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019;20:948–960.)| false
• Search Google Scholar
• Export Citation

Reijers ILM, Menzies AM, van Akkooi AC, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 2022;28:1178–1188.

• PubMed
Reijers ILM, Menzies AM, van Akkooi AC, Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 2022;28:1178–1188.)| false
• Search Google Scholar
• Export Citation

Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 2022;611:155–160.

• PubMed
Amaria RN, Postow M, Burton EM, Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 2022;611:155–160.)| false
• Search Google Scholar
• Export Citation

Patel SP, Othus M, Chen Y, et al. Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388:813–823.

• PubMed
Patel SP, Othus M, Chen Y, Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388:813–823.)| false
• Search Google Scholar
• Export Citation

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 2022;40:127–137.

• PubMed
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 2022;40:127–137.)| false
• Search Google Scholar
• Export Citation

Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018;19:672–681.

• PubMed
Long GV, Atkinson V, Lo S, Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018;19:672–681.)| false
• Search Google Scholar
• Export Citation

Long GV, Hodi FS, Lipson EJ, et al. Overall survival and response with nivolumab and relatlimab in advanced melanoma. NEJM Evid 2023;2:EVIDoa2200239.

• PubMed
Long GV, Hodi FS, Lipson EJ, Overall survival and response with nivolumab and relatlimab in advanced melanoma. NEJM Evid 2023;2:EVIDoa2200239.)| false
• Search Google Scholar
• Export Citation

Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial—ECOG-ACRIN EA6134. J Clin Oncol 2023;41:186–197.

• PubMed
Atkins MB, Lee SJ, Chmielowski B, Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial—ECOG-ACRIN EA6134. J Clin Oncol 2023;41:186–197.)| false
• Search Google Scholar
• Export Citation

VanderWalde A, Bellasea SL, Kendra KL, et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med 2023;29:2278–2285.

• PubMed
VanderWalde A, Bellasea SL, Kendra KL, Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med 2023;29:2278–2285.)| false
• Search Google Scholar
• Export Citation

Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer 2022;10:e005755.

• PubMed
Chesney J, Lewis KD, Kluger H, Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer 2022;10:e005755.)| false
• Search Google Scholar
• Export Citation

Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med 2022;387:2113–2125.

• PubMed
Rohaan MW, Borch TH, van den Berg JH, Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med 2022;387:2113–2125.)| false
• Search Google Scholar
• Export Citation